Editing Labor induction (section)

===Medication===
* [[Intravaginal administration|Intravaginal]], endocervical or [[extra-amniotic administration]] of [[prostaglandin]], such as [[Prostaglandin E2|dinoprostone]] or [[misoprostol]].<ref name="pmid15043790">{{cite journal |vauthors=Li XM, Wan J, Xu CF, Zhang Y, Fang L, Shi ZJ, Li K |title=Misoprostol in labor induction of term pregnancy: a meta-analysis|journal=Chin Med J (Engl)|volume=117 |issue=3 |pages=449–52 |date=March 2004 |pmid=15043790 }}</ref> [[Prostaglandin E2]] is the most studied compound and with most evidence behind it.{{Citation needed|date=August 2018}} A range of different dosage forms are available with a variety of routes possible. The use of misoprostol has been extensively studied but normally in small, poorly defined studies. Only a very few countries have approved [[misoprostol]] for use in induction of labor.{{Citation needed|date=August 2018}}
* [[Intravenous therapy|Intravenous]] (IV) administration of synthetic [[oxytocin]] preparations is used to artificially induce labor if it is deemed medically necessary.<ref name=":0" /> A high dose of oxytocin does not seem to have greater benefits than a standard dose.<ref>{{cite journal|last1=Budden|first1=A|last2=Chen|first2=LJ|last3=Henry|first3=A|title=High-dose versus low-dose oxytocin infusion regimens for induction of labour at term.|journal=The Cochrane Database of Systematic Reviews|date=Oct 9, 2014|volume=10|issue=10|pages=CD009701|pmid=25300173|doi=10.1002/14651858.CD009701.pub2|pmc=8932234|s2cid=205201341}}</ref> There are risks associated with IV oxytocin induced labor. Risks include the women having induced contractions that are too vigorous, too close together (frequent), or that last too long, which may lead to added stress on the baby (changes in baby's heart rate) and may require the mother to have an emergency [[caesarean section]].<ref name=":0" /> There is no high quality evidence to indicate if IV oxytocin should be stopped once a woman reaches active labor in order to reduce the incidence of women requiring caesarean sections.<ref name=":0">{{Cite journal|last1=Boie|first1=Sidsel|last2=Glavind|first2=Julie|last3=Velu|first3=Adeline V.|last4=Mol|first4=Ben Willem J.|last5=Uldbjerg|first5=Niels|last6=de Graaf|first6=Irene|last7=Thornton|first7=Jim G.|last8=Bor|first8=Pinar|last9=Bakker|first9=Jannet Jh|date=2018-08-20|title=Discontinuation of intravenous oxytocin in the active phase of induced labour|journal=The Cochrane Database of Systematic Reviews|volume=2018|issue=8|pages=CD012274|doi=10.1002/14651858.CD012274.pub2 |pmid=30125998|pmc=6513418}}</ref>
* Use of [[mifepristone]] has been described but is rarely used in practice.<ref name="pmid16647925">{{cite journal |vauthors=Clark K, Ji H, Feltovich H, Janowski J, Carroll C, Chien EK |title=Mifepristone-induced cervical ripening: structural, biomechanical, and molecular events |journal=Am. J. Obstet. Gynecol. |volume=194 |issue=5 |pages=1391–8 |date=May 2006 |pmid=16647925 |doi=10.1016/j.ajog.2005.11.026 }}</ref>
* [[Relaxin]] has been investigated,<ref name="pmid11406079">{{cite journal |vauthors=Kelly AJ, Kavanagh J, Thomas J |title=Relaxin for cervical ripening and induction of labor |journal=Cochrane Database Syst Rev |issue=2 |pages=CD003103 |year=2001 |volume=2010 |pmid=11406079 |doi=10.1002/14651858.CD003103 |pmc=8693181 }}</ref> but is not currently commonly used.
* mnemonic; ARNOP: [[Antiprogestogen|Antiprogesterone]], relaxin, [[nitric oxide]] donors, oxytocin, prostaglandins